Eighty children with non-localized neuroblastoma were treated in a randomized clinical trial, either with chemotherapy alone (cyclophosphamide and doxorubicin in monthly sequential cycles), or with the same chemotherapy associated with the thymic extract TP-1 (Serono) given in the intervals between chemotherapy cycles. TP-1 administration did not influence immune status, as assessed by total white blood cell count, total lymphocyte count and T and B cell count, levels of serum immunoglobulins (IgG, IgA, IgM), and of complement fractions C3-C4. Percentages of patients achieving either complete or partial remission, or percentages of survivors, were not significantly affected; however, patients receiving TP-1 developed significantly less infectious episodes than the control group.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health